Indications to begin antiviral therapy in patients with chronic HBV without concern for significant hepatic fibrosis 
are: 1) ALT >2 times the upper limit of normal and HBV DNA >2,000 IU/mL for HBeAg negative patients, 
or 2) ALT >2 times the upper limit of normal and HBV DNA >20,000 IU/mL for HBeAg positive patients. 
